A Corthay

Summary

Affiliation: University of Oslo
Country: Norway

Publications

  1. ncbi Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models
    Alexandre Corthay
    University of Oslo, Institute of Immunology, Rikshospitalet University Hospital, N 0027 Oslo, Norway
    Cancer Immunol Immunother 53:759-69. 2004
  2. pmc Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
    Ole Audun Werner Haabeth
    Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway
    Nat Commun 2:240. 2011
  3. doi Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer
    A Corthay
    Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway
    Scand J Immunol 73:527-30. 2011
  4. pmc How do regulatory T cells work?
    A Corthay
    Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway
    Scand J Immunol 70:326-36. 2009
  5. doi Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells
    Alexandre Corthay
    Center for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway
    Cancer Res 69:5901-7. 2009
  6. ncbi CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells
    Alexandre Corthay
    Institute of Immunology, University of Oslo and Rikshospitalet Radiumhospitalet Medical Center, 0027 Oslo, Norway
    Adv Exp Med Biol 590:195-208. 2007
  7. ncbi A three-cell model for activation of naïve T helper cells
    A Corthay
    Institute of Immunology, University of Oslo and Rikshospitalet Radiumhospitalet Medical Center, Oslo, Norway
    Scand J Immunol 64:93-6. 2006
  8. ncbi Primary antitumor immune response mediated by CD4+ T cells
    Alexandre Corthay
    Institute of Immunology, University of Oslo, Rikshospitalet and Rikshospitalet University Hospital, 0027 Oslo, Norway
    Immunity 22:371-83. 2005
  9. ncbi Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies
    Katrin U Lundin
    Institute of Immunology, University of Oslo, Rikshospitalet University Hospital, Oslo, Norway
    Blood 102:605-12. 2003
  10. ncbi Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells
    Ludvig André Munthe
    Institute of Immunology, University of Oslo, Rikshospitalet University Hospital, Oslo, Norway
    J Immunol 175:2391-400. 2005

Collaborators

Detail Information

Publications15

  1. ncbi Immunotherapy in multiple myeloma: Id-specific strategies suggested by studies in animal models
    Alexandre Corthay
    University of Oslo, Institute of Immunology, Rikshospitalet University Hospital, N 0027 Oslo, Norway
    Cancer Immunol Immunother 53:759-69. 2004
    ....
  2. pmc Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer
    Ole Audun Werner Haabeth
    Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway
    Nat Commun 2:240. 2011
    ..Thus, inflammation, when driven by tumour-specific Th1 cells, may prevent rather than promote cancer...
  3. doi Is secretion of tumour-specific antigen important for cancer eradication by CD4(+) T cells?--Implications for cancer immunotherapy by adoptive T cell transfer
    A Corthay
    Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital Rikshospitalet, Oslo, Norway
    Scand J Immunol 73:527-30. 2011
    ..Thus, it is anticipated that secreted TSA will be more readily detected in vivo by transferred CD4(+) T cells, resulting in more efficient tumour eradication...
  4. pmc How do regulatory T cells work?
    A Corthay
    Centre for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway
    Scand J Immunol 70:326-36. 2009
    ..Recent reports have also demonstrated that Foxp3(+) Treg cells may differentiate in vivo into conventional effector Th cells, with or without concomitant downregulation of Foxp3...
  5. doi Secretion of tumor-specific antigen by myeloma cells is required for cancer immunosurveillance by CD4+ T cells
    Alexandre Corthay
    Center for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway
    Cancer Res 69:5901-7. 2009
    ..Collectively, the data indicate that antigen concentration within the tumor extracellular matrix must reach a certain threshold to allow successful cancer immunosurveillance by CD4(+) T cells...
  6. ncbi CD4+ T cells cooperate with macrophages for specific elimination of MHC class II-negative cancer cells
    Alexandre Corthay
    Institute of Immunology, University of Oslo and Rikshospitalet Radiumhospitalet Medical Center, 0027 Oslo, Norway
    Adv Exp Med Biol 590:195-208. 2007
  7. ncbi A three-cell model for activation of naïve T helper cells
    A Corthay
    Institute of Immunology, University of Oslo and Rikshospitalet Radiumhospitalet Medical Center, Oslo, Norway
    Scand J Immunol 64:93-6. 2006
    ..The rationale behind this model is that the innate immune system has been designed by evolution to select an appropriate class of immune response to protect the host...
  8. ncbi Primary antitumor immune response mediated by CD4+ T cells
    Alexandre Corthay
    Institute of Immunology, University of Oslo, Rikshospitalet and Rikshospitalet University Hospital, 0027 Oslo, Norway
    Immunity 22:371-83. 2005
    ..These data indicate a mechanism for immunosurveillance of MHC-II-negative cancer cells by tumor-specific CD4+ T cells through collaboration with macrophages...
  9. ncbi Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies
    Katrin U Lundin
    Institute of Immunology, University of Oslo, Rikshospitalet University Hospital, Oslo, Norway
    Blood 102:605-12. 2003
    ..The results show that Id-specific CD4+ T cells, in the absence of antibodies home to subcutaneous Id+ B lymphoma, become activated, induce inflammation, and prevent tumor development...
  10. ncbi Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells
    Ludvig André Munthe
    Institute of Immunology, University of Oslo, Rikshospitalet University Hospital, Oslo, Norway
    J Immunol 175:2391-400. 2005
    ....
  11. ncbi Idiotype-specific immunotherapy in multiple myeloma: suggestions for future directions of research
    Bjarne Bogen
    Institute of Immunology, University of Oslo, Rikshospitalet University Hospital N 0027 Oslo, Norway
    Haematologica 91:941-8. 2006
    ..This review focuses on tolerance mechanisms that might hinder Id-specific immune responses in MM patients. New strategies for Id vaccination in MM are discussed...
  12. ncbi Evaluation of the percentage of peripheral T cells with two different T cell receptor alpha-chains and of their potential role in autoimmunity
    A Corthay
    Institute of Immunology, University of Oslo, The National Hospital, Oslo, 0027, Norway
    J Autoimmun 16:423-9. 2001
    ....
  13. doi Isoform-specific regulation of immune cell reactivity by the catalytic subunit of protein kinase A (PKA)
    Ane Funderud
    Department of Nutrition, Institute of Basic Medical Sciences, University of Oslo, Norway
    Cell Signal 21:274-81. 2009
    ..Our results imply that Calpha is required for normal immune cell reactivity and demonstrates isoform-specific effects and non-redundant functions of C subunit isoforms expressed in the same cell...
  14. ncbi Monoclonal antibodies produced by muscle after plasmid injection and electroporation
    Torunn Elisabeth Tjelle
    Inovio AS, Forskningsveien 2a, 0373 Oslo, Norway
    Mol Ther 9:328-36. 2004
    ..Sustained levels of serum mAb, induced by single injection of Ig genes and electroporation of muscle cells, may offer significant advantages in the treatment of human diseases...